In her closing remarks, Dr. Kotton also touched on issues of infectious disease prevention in children with juvenile idiopathic arthritis and urged her colleagues to make use of the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System to help add to the knowledge base about zoster vaccines in immunosuppressed patients.5
You Might Also Like
Explore This IssueAugust 2009
Also By This Author
- Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune disease. Clin Infect Dis. 2008;46:1459-1465.
- Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.
- Oxman MN, Levin MJ. Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197 Suppl 2:S228-S238.
- Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention. Prevention of herpes zoster: Recommendations from the Advisory Committee on Immunization Practices. MMWR Recomm Rep. June 6, 2008;57:1-30.
- Centers for Disease Control and Prevention; Food and Drug Administration. Vaccine Adverse Event Reporting System. Available at: http://vaers.hhs.gov/vaers.htm. Accessed May 17, 2009.